RESEARCH PAPER

Bioanalytical Method Development and Validation: Principles, Regulatory Frameworks, Techniques, and Emerging Trends

Megha Sahebrao Jadhav*, Dr. Dhanashri Revnath Mali, Dr. Sunil V. Amrutkar
Department of Pharmaceutical Chemistry, Sir, Dr. M.S. Gosavi College of Pharmaceutical Education and Research, Nashik 422005, Maharashtra, India
***Corresponding author: Megha Sahebrao Jadhav, Department of Pharmaceutical Chemistry, Sir, Dr. M.S. Gosavi College of Pharmaceutical Education and Research, Nashik 422005, Maharashtra, India**
Email: megha.jadhav2705@gmail.com
Received: 25th May, 2026; **Revised:** 6th June, 2026; **Accepted:** 8th June, 2026; **Available Online:** 20th June, 2026

ABSTRACT
Bioanalysis represents a cornerstone discipline within pharmaceutical sciences, dedicated to the qualitative and quantitative determination of drugs, metabolites, biomarkers, and endogenous compounds across diverse biological matrices including plasma, serum, urine, saliva, and tissues. The generation of accurate and reliable bioanalytical data is indispensable for drug discovery, preclinical evaluation, clinical development, therapeutic drug monitoring, bioavailability, bioequivalence, and regulatory submissions. Over time, bioanalytical methodologies have undergone significant evolution, progressing from conventional chromatographic techniques to advanced analytical platforms such as liquid chromatography–tandem mass spectrometry (LC–MS/MS), high-resolution mass spectrometry (HRMS), and ligand-binding assays (LBAs). Method development encompasses systematic optimization of sample preparation, chromatographic separation, detection systems, and analytical conditions to ensure robust and reproducible performance. Validation of bioanalytical methods is a critical process that establishes reliability, accuracy, precision, selectivity, sensitivity, recovery, stability, and reproducibility, thereby confirming suitability for regulatory and scientific applications. International regulatory authorities, including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), the World Health Organization (WHO), and the International Council for Harmonisation (ICH), have issued comprehensive guidelines to standardize validation practices, with the ICH M10 guideline providing a globally harmonized framework. Despite remarkable technological advancements, persistent challenges such as matrix effects, analyte instability, limited sample volumes, and the increasing complexity of biologics continue to shape bioanalytical research. Recent innovations—including ultra-performance liquid chromatography (UPLC), micro sampling technologies, automation, artificial intelligence, and biomarker-driven analysis—have expanded analytical capabilities, improved efficiency, and broadened the scope of bioanalysis. This review offers a comprehensive synthesis of bioanalytical method development, validation principles, regulatory frameworks, prevailing challenges, and emerging trends, underscoring the pivotal role of bioanalysis in contemporary drug development and personalized medicine.
Keywords: Bioanalysis, Bioanalytical Method Validation, LC–MS/MS, Pharmacokinetics, ICH M10 Guidelines.
How to cite this article: Jadhav MS, Mali DR, Amrutkar SV. Bioanalytical Method Development and Validation: Principles, Regulatory Frameworks, Techniques, and Emerging Trends. Int J Drug Deliv Technol. 2026;16(62s): 963-977. DOI: 10.25258/ijddt.16.62s.104
Source of support: Nil.
Conflict of interest: None.

INTRODUCTION

Bioanalysis is a specialized discipline within pharmaceutical sciences that encompasses the qualitative and quantitative determination of drugs, metabolites, biomarkers, and endogenous compounds in biological matrices such as blood, plasma, serum, urine, saliva, tissues, and feces. It plays a pivotal role in pharmaceutical research by enabling precise measurement of analytes in complex biological systems, thereby facilitating the evaluation of drug safety, efficacy, and pharmacokinetic behaviour. With the rapid advancement of modern therapeutics and the growing demands of regulatory authorities, bioanalysis has evolved into a highly sophisticated and stringently regulated field [1,2].

Reliable bioanalytical data are indispensable for pharmacokinetic (PK), pharmacodynamic (PD), toxicokinetic (TK), bioavailability (BA), and bioequivalence (BE) studies. These investigations establish the absorption, distribution, metabolism, and excretion (ADME) profile of drug candidates and provide the scientific basis for dose selection during drug development [3]. Historically, chromatographic techniques such as gas chromatography (GC) and high-performance liquid chromatography (HPLC) were extensively employed for small-molecule bioanalysis. The

introduction of liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) revolutionized the discipline by offering unparalleled sensitivity, selectivity, and analytical throughput [4,5].

The rise of biologics—including monoclonal antibodies, peptides, recombinant proteins, and antibody–drug conjugates—has further expanded the scope of bioanalysis. These complex therapeutic agents often necessitate specialized analytical approaches such as ligand-binding assays (LBAs), enzyme-linked immunosorbent assays (ELISA), and hybrid LC–MS/MS platforms for accurate quantification and characterization [6]. Consequently, modern bioanalytical laboratories integrate chromatographic, spectrometric, and immunological techniques to address diverse analytical challenges encountered throughout drug development.

Bioanalytical method validation is a fundamental component of this discipline, ensuring that analytical methods are fit for purpose. Validation confirms the reliability, reproducibility, accuracy, precision, selectivity, sensitivity, and stability of measurements. Regulatory agencies such as the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Council for Harmonisation (ICH) have established guidelines to standardize validation practices globally [7,8]. The introduction of the ICH M10 Guideline on Bioanalytical Method Validation and Study Sample Analysis represents a significant milestone, providing a harmonized framework that reduces regulatory inconsistencies and promotes uniformity in data quality across pharmaceutical studies [9].

Today, bioanalysis serves as the cornerstone of evidence-based drug development, supporting critical decisions from early discovery through clinical development, regulatory approval, and post-marketing surveillance. The accuracy and reliability of bioanalytical methods directly influence scientific interpretation, regulatory confidence, and ultimately patient safety and therapeutic success [10].

Figure 1. Role of Bioanalysis in Drug Development

Role of Bioanalysis in Drug Development

1. **Role in Drug Discovery and Lead Optimization** In the initial stages of drug discovery, bioanalytical techniques play a vital role in identifying and optimizing lead compounds. Quantitative analysis of candidate molecules provides essential insights into their absorption, distribution, metabolism, and excretion (ADME) characteristics. High-throughput bioanalytical platforms enable rapid screening of multiple compounds, facilitating the selection of candidates with favorable pharmacokinetic properties and reduced toxicity risks [2,5].
2. **Role in Preclinical Research** During preclinical development, bioanalysis supports pharmacokinetic and toxicokinetic studies conducted in animal models. Measurement of drug and metabolite concentrations in plasma, tissues, and excreta helps establish exposure–response relationships and determine safe starting doses for human clinical trials. These studies are crucial for assessing tissue distribution, accumulation, and toxicological effects associated with drug exposure [4,10].
3. **Role in Clinical Pharmacokinetic and Pharmacodynamic Studies** Clinical drug development relies heavily on bioanalytical measurements for determining pharmacokinetic and pharmacodynamic parameters. Quantification of drug concentrations at various time points enables calculation of Cmax, Tmax, AUC, clearance, volume of distribution, and elimination half-life. These parameters guide dose optimization and therapeutic regimen design while supporting PK–PD modeling and exposure–response analysis [3,6].
4. **Role in Bioavailability and Bioequivalence Studies** Bioanalytical methods are fundamental to bioavailability and bioequivalence studies required for generic drug approval and formulation development. Accurate measurement of drug concentrations in biological samples allows comparison between test and reference products. Regulatory acceptance of BA/BE studies depends significantly on the reliability and validation status of the bioanalytical method employed [7,8].
5. **Role in Therapeutic Drug Monitoring and Personalized Medicine** Therapeutic drug monitoring involves measuring drug

concentrations in patient samples to optimize therapeutic outcomes and minimize toxicity. Bioanalysis is particularly important for drugs with narrow therapeutic indices and high interindividual variability. Advances in personalized medicine have further expanded the role of bioanalysis through biomarker-guided dosing and individualized treatment strategies [6,9].

6. **Role in Biologics and Advanced Therapeutics** The increasing use of biologics has introduced new analytical challenges that require specialized bioanalytical methodologies. Ligand-binding assays and hybrid analytical platforms are widely employed for the characterization of monoclonal antibodies, recombinant proteins, and antibody–drug conjugates. These techniques support immunogenicity assessment, pharmacokinetic evaluation, and stability studies of biologic products [1,6].
7. **Role in Regulatory Decision-Making and Post-Marketing Surveillance** Regulatory agencies rely extensively on bioanalytical data to evaluate the safety and efficacy of pharmaceutical products. Validated bioanalytical methods ensure the credibility of data submitted in regulatory applications. Following product approval, bioanalysis continues to play an essential role in pharmacovigilance, therapeutic monitoring, and long-term safety assessment, thereby contributing to sustained patient protection and regulatory confidence [8–10].

Table 1. Major Applications of Bioanalysis in Drug Development

Development Stage	Bioanalytical Application	Outcome
Drug Discovery	Lead screening and ADME evaluation	Candidate selection
Preclinical Development	PK and TK studies	Safe dose determination
Clinical Trials	PK/PD studies	Dose optimization
BA/BE Studies	Product comparison	Regulatory approval
Therapeutic Drug Monitoring	Drug level monitoring	Personalized therapy
Biologics Development	Immunogenicity assessment	Biologic characterization
Post-Marketing Surveillance	Safety monitoring	Risk management

Biological Matrices and Sample Handling

The reliability of bioanalytical data is determined not only by the analytical techniques employed but also by the careful selection, collection, processing, and storage of biological samples. Biological matrices inherently contain complex endogenous components that may interfere with analyte detection and quantification. Therefore, stringent sample handling procedures are essential to preserve analyte stability, prevent contamination, and ensure the accuracy and reproducibility of analytical results [11,12].

Common Biological Matrices

Biological matrices serve as the primary media in which drugs, metabolites, biomarkers, and endogenous compounds are measured. The choice of matrix depends on the study objectives, the pharmacokinetic characteristics of the analyte, and the required analytical sensitivity. Plasma and serum are the most widely used matrices in pharmacokinetic and bioequivalence studies because they directly reflect systemic drug exposure. Urine is frequently employed in excretion studies and metabolite profiling, while saliva provides valuable information about the free, pharmacologically active fraction of a drug. Tissue samples are utilized in biodistribution studies to evaluate drug penetration and accumulation, whereas fecal samples are important for assessing drug elimination and metabolism pathways [11,13].

Table 2. Common Biological Matrices Used in Bioanalysis

Biological Matrix	Major Application	Advantages
Plasma	Pharmacokinetic studies	Reflects systemic drug exposure
Serum	Clinical monitoring	Easy sample processing
Urine	Excretion and metabolite studies	Non-invasive collection
Saliva	Free drug concentration monitoring	Convenient and painless collection
Tissue	Distribution studies	Site-specific drug analysis
Feces	Metabolism and elimination studies	Assessment of biliary excretion

Sample Collection

Proper sample collection represents the first and most critical step in bioanalysis, as any errors introduced during this stage can compromise sample integrity and ultimately lead to inaccurate results. Blood samples are typically collected using anticoagulants such as ethylenediaminetetraacetic acid (EDTA), heparin, or citrate, depending on the

specific analytical requirements. Following collection, samples are centrifuged under controlled conditions to separate plasma or serum from cellular components. The use of standardized collection procedures is essential to minimize variability and ensure consistency across study samples [14].

For other biological matrices such as urine, saliva, and tissue, carefully designed collection protocols must be implemented to prevent contamination and analyte degradation. Accurate documentation of collection time, storage conditions, and processing steps is equally important, as it ensures data integrity and traceability throughout the study [15].

Sample Processing

Biological matrices inherently contain proteins, phospholipids, salts, and other endogenous compounds that may interfere with analytical measurements. Consequently, sample preparation is required prior to instrumental analysis. The primary objectives of sample processing are to eliminate interfering substances, improve analyte recovery, and enhance analytical sensitivity [16].

Commonly employed sample preparation techniques include protein precipitation (PPT), which is a simple and rapid method for protein removal; liquid–liquid extraction (LLE), which separates analytes based on differential solubility between aqueous and organic phases; solid-phase extraction (SPE), which provides selective purification using sorbent materials; and microextraction techniques, which represent advanced approaches offering reduced solvent consumption and higher sensitivity. The choice of extraction technique depends on analyte properties, matrix complexity, required sensitivity, and the analytical platform employed [16,17].

Sample Stability and Storage

Many analytes are prone to chemical degradation, enzymatic metabolism, oxidation, hydrolysis, or adsorption during storage and analysis. Therefore, maintaining appropriate storage conditions is critical to preserve sample integrity. Biological samples are generally stored under refrigerated or frozen conditions, depending on the stability characteristics of the analyte [18].

Stability studies are conducted during method validation to demonstrate that analyte concentrations remain unchanged throughout collection, processing, storage, and analysis. Several types of stability assessments are routinely performed, including short-term (bench-top) stability, long-term storage stability, freeze–thaw stability, processed sample stability, and stock solution stability. Acceptance criteria typically require measured concentrations to remain within ±15% of nominal values to ensure reliable quantification [18,19].



Figure 2: General Workflow of Biological Sample Handling

Bioanalytical Method Development

Bioanalytical method development is a systematic and scientifically driven process aimed at establishing a reliable, accurate, sensitive, and reproducible analytical procedure for the identification and quantification of drugs, metabolites, biomarkers, and endogenous compounds in biological matrices. The inherent complexity of biological samples, combined with the typically low concentration of analytes, necessitates meticulous optimization of sample preparation, chromatographic separation, detection systems, and data analysis procedures. A well-developed bioanalytical method forms the foundation for successful pharmacokinetic, toxicokinetic, bioavailability, bioequivalence, and therapeutic drug monitoring studies [20,21].

The selection of an appropriate bioanalytical method depends on multiple factors, including the physicochemical properties of the analyte, expected concentration range, biological matrix, sensitivity requirements, sample throughput, regulatory expectations, and available instrumentation. During method development, parameters such as extraction efficiency, selectivity, chromatographic resolution, analyte stability, and detector response are systematically optimized to ensure robust and reliable analytical performance [21,22].

Steps Involved in Bioanalytical Method Development

The development of a bioanalytical method generally follows a structured workflow that begins with analyte characterization and culminates in method validation. Each stage contributes to achieving optimal analytical performance and ensuring compliance with regulatory standards. The process typically includes:

1. **Analyte Characterization:** Understanding the physicochemical

properties of the analyte, including molecular weight, polarity, solubility, and stability, to guide method selection.

2. **Selection of Analytical Technique:** Choosing an appropriate analytical platform such as HPLC, LC–MS/MS, or LBA based on analyte characteristics and study requirements.
3. **Optimization of Sample Preparation:** Developing efficient extraction and cleanup procedures to remove interferences and enhance analyte recovery.
4. **Chromatographic Separation:** Establishing suitable mobile phase composition, column type, flow rate, and temperature to achieve optimal resolution and peak shape.
5. **Detection and Quantification:** Selecting and calibrating the detector system to ensure sensitivity, selectivity, and reproducibility of measurements.
6. **System Suitability Testing:** Evaluating instrument performance parameters such as retention time, peak area, resolution, and theoretical plates before analysis.
7. **Method Validation:** Confirming accuracy, precision, selectivity, sensitivity, linearity, recovery, and stability to ensure the method meets regulatory and scientific standards.

Each of these steps is interdependent, collectively ensuring that the developed bioanalytical method is robust, reproducible, and compliant with international regulatory guidelines.



Figure 3. General Workflow of Bioanalytical Method Development

Sample Preparation Techniques

Sample preparation is one of the most critical stages in bioanalysis because biological matrices contain proteins, lipids, salts, and endogenous substances that can interfere with analyte detection. Effective sample preparation enhances analyte recovery, improves sensitivity, and minimizes matrix effects [22].

1. Protein Precipitation (PPT) Protein precipitation is the simplest and most widely used sample preparation technique. It involves adding organic solvents such as methanol or acetonitrile to denature and precipitate proteins present in biological samples. After centrifugation, the supernatant containing the analyte is collected for analysis.

Advantages

- Simple and rapid procedure
- Low solvent consumption
- Suitable for high-throughput analysis

Limitations

- Limited sample clean-up
- Potential matrix interferences
- Reduced sensitivity for trace-level analytes

Protein precipitation is commonly employed in routine LC–MS/MS bioanalysis due to its simplicity and cost-effectiveness [23].

2. Liquid–Liquid Extraction (LLE) Liquid–liquid extraction separates analytes based on their differential partitioning between aqueous and organic phases. The analyte is transferred from the biological matrix into an immiscible organic solvent, leaving many endogenous impurities behind.

Advantages

- Good sample clean-up
- High analyte recovery
- Reduced matrix effects

Limitations

- Labor-intensive procedure
- Large solvent requirement
- Difficult automation

LLE remains a valuable extraction approach for non-polar and moderately polar compounds [24].

3. Solid-Phase Extraction (SPE) Solid-phase extraction is a selective sample preparation technique in which analytes are retained on a solid sorbent while interfering substances are removed through washing steps. The analyte is subsequently eluted using an appropriate solvent.

Advantages

- High selectivity
- Excellent sample clean-up
- Improved reproducibility
- Suitable for trace-level analysis

Limitations

- Higher operational cost
- Method optimization required

Due to its superior extraction efficiency and cleaner extracts, SPE is widely regarded as the preferred

sample preparation technique for bioanalytical applications [25].



Figure 4: Solid Phase Extraction (SPE)

Chromatographic Methods in Bioanalysis

Chromatographic techniques are among the most important analytical tools used for separating analytes from complex biological matrices. These methods provide high selectivity, sensitivity, and quantitative accuracy.

High-Performance Liquid Chromatography (HPLC)

HPLC is extensively used for the analysis of pharmaceutical compounds and metabolites. Separation occurs based on differential interactions between analytes, the stationary phase, and the mobile phase. HPLC systems generally consist of a solvent reservoir, pump, injector, chromatographic column, detector, and data acquisition system [26].

Table 3. Major Components of an HPLC System

Component	Function
Solvent Reservoir	Stores mobile phase
Pump	Delivers mobile phase under pressure
Injector	Introduces sample into system
Column	Performs analyte separation
Detector	Detects separated compounds
Data System	Records and processes data

The selection of mobile phase composition, flow rate, column chemistry, and detection wavelength plays a decisive role in determining chromatographic performance and analytical reliability [26,27].



Figure 5: HPLC Schematic Diagram

1. Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS) LC–MS/MS has emerged as the gold standard technique in modern bioanalysis due to its exceptional sensitivity, specificity, and capability to quantify analytes at trace levels. This technique integrates chromatographic separation with mass spectrometric detection, enabling highly selective identification and quantification of compounds based on their mass-to-charge (m/z) ratios [27].

Advantages of LC–MS/MS

- Extremely high sensitivity
- Excellent selectivity
- Simultaneous multi-analyte detection
- Minimal sample volume requirement
- Rapid analysis

LC–MS/MS is extensively utilized in pharmacokinetic, toxicokinetic, and bioequivalence studies where precise quantification at nanogram or picogram concentrations is required [21,27].

2. Ligand-Binding Assays (LBAs) Ligand-binding assays are widely applied for the quantification of large biomolecules such as proteins, peptides, cytokines, monoclonal antibodies, and biomarkers. These assays rely on highly specific interactions between analytes and biological recognition elements such as antibodies or receptors [28].

Common Ligand-Binding Assay Formats

- Enzyme-Linked Immunosorbent Assay (ELISA)
- Electrochemiluminescence Immunoassay (ECLIA)
- Radioimmunoassay (RIA)
- Fluorescence-Based Immunoassays

LBAs offer exceptional sensitivity and selectivity for biologics and are frequently employed alongside LC–MS/MS in contemporary bioanalytical laboratories to achieve comprehensive characterization and quantification of both small and large molecules [28].

Table 4. Comparison of Major Bioanalytical Techniques

Technique	Analyte Type	Sensitivity	Selectivity	Common Applications
HPLC-UV	Small molecules	Moderate	Moderate	Routine drug analysis
LC–MS/MS	Small molecules, metabolites	Very High	Very High	PK, TK, BA/BE studies
ELISA	Proteins, biomarkers	High	High	Biologics analysis
ECLIA	Monoclonal antibodies	Very High	Very High	Immunogenicity studies
GC-MS	Volatile compounds	High	High	Metabolite analysis

Bioanalytical Method Validation

Introduction Bioanalytical method validation is a documented and structured process designed to demonstrate the reliability, reproducibility, and suitability of an analytical method for its intended application. The primary objective of validation is to ensure that the method consistently delivers accurate and precise results when quantifying analytes in biological matrices. Since bioanalytical data underpin pharmacokinetic, toxicokinetic, bioavailability, bioequivalence, and clinical studies, regulatory agencies mandate comprehensive validation of analytical methods prior to their routine use [29,30].

Validation establishes confidence in the generated data by evaluating critical performance parameters such as selectivity, sensitivity, accuracy, precision, recovery, matrix effects, stability, and calibration performance. International regulatory authorities, including the FDA, EMA, and ICH, have issued harmonized guidelines to standardize bioanalytical validation practices globally. The implementation of the ICH M10 guideline has further strengthened consistency in bioanalytical method validation and study sample analysis worldwide [31].

Types of Bioanalytical Method Validation

Depending on the purpose of the analytical method and the extent of modifications introduced, bioanalytical validation can be classified into three categories:

1. **Full Validation**
   - Conducted when a new analytical method is developed for a novel analyte or biological matrix.
   - Requires thorough evaluation of all validation parameters in accordance with regulatory requirements.
2. **Partial Validation**
   - Performed when minor modifications are made to an already validated method.
   - Examples include changes in matrix type, analytical instrument, sample volume, or concentration range.
3. **Cross Validation**
   - Required when data generated using different analytical methods or laboratories must be compared.
   - Ensures consistency and comparability of analytical results across methods and study sites [29,32].



Figure 6: Types of Bioanalytical Method Validation

Validation Parameters

Selectivity

Selectivity defines the ability of an analytical method to distinguish and quantify the analyte in the presence of endogenous matrix components, metabolites, degradation products, and concomitant medications. It is evaluated by analyzing blank biological samples from multiple independent sources to confirm the absence of interfering peaks at the analyte and internal standard retention times [30].

Sensitivity and Lower Limit of Quantification (LLOQ)

Sensitivity represents the capability of a method to accurately measure low analyte concentrations. The Lower Limit of Quantification (LLOQ) is the lowest concentration that can be quantified with acceptable accuracy and precision.

For an LLOQ sample:

- **Accuracy:** within ±20%
- **Precision:** ≤20% coefficient of variation (CV)

LLOQ is crucial in pharmacokinetic studies where drug concentrations may be extremely low during terminal elimination phases [31].

Calibration Curve and Linearity

A calibration curve establishes the relationship between analyte concentration and detector response. Calibration standards are prepared by spiking known analyte concentrations into the biological matrix and analyzing them under identical conditions.

A typical calibration curve should:

- Cover the expected concentration range
- Include at least six to eight non-zero calibration points
- Demonstrate acceptable correlation and reproducibility

Accuracy

The accuracy of an analytical method describes the closeness of test results obtained by the method to the true value of the analyte. Accuracy is determined by replicate analysis of samples containing known amounts of the analyte. Accuracy should be measured using a minimum of five determinations per concentration. A minimum of three concentrations in the range of expected. The mean value should be within 15% of the actual value except at LLOQ, where it should not deviate by more than 20%. The deviation of the mean from the true value serves as the measure of accuracy. [29]

Accuracy can be determined through two main approaches:

(1) Analyzing control samples spiked with the analyte and

(2) Comparing the analytical method with a reference method.

Accuracy is typically expressed as percentage bias, which is calculated using a specific formula.

$$\text{Abso\%Bias} = \frac{\text{measured value} - \text{true value}}{\text{True value}} \times 100$$

Precision

The precision of a bioanalytical method refers to its ability to produce consistent results when the same homogeneous sample is analyzed multiple times under identical conditions. It assesses the extent of random errors by measuring how closely the results of repeated measurements align with one another. Precision is commonly expressed as the coefficient of variation (%CV) or the relative standard deviation (R.S.D.) of the repeated measurements, indicating the degree of variation in the observed values for the same sample. This ensures reliability in the method's performance.

$$\%CV = \frac{\text{Standard Deviation}}{\text{Mean Measured Concentration}} \times 100$$

Precision should be assessed using at least five measurements for each concentration, with a minimum of three different concentrations spanning the expected range. At each concentration level, the precision, expressed as the coefficient of variation (CV), should not exceed 15%, except at the limit of quantification (LOQ), where it may go up to 20%. Precision can be evaluated at three distinct levels: repeatability, intermediate precision, and reproducibility.[30]

Recovery

Recovery represents the extraction efficiency of an analyte from a biological matrix during sample preparation. It is determined by comparing the analytical response from extracted samples with that from unextracted standards at equivalent concentrations.

Recovery should be:

- Consistent
- Reproducible
- Independent of concentration level

High and reproducible recovery enhances assay sensitivity and reliability [32].

Matrix Effect

Matrix effects occur when endogenous components alter analyte ionization during mass spectrometric analysis, causing ion suppression or enhancement.

Table 5. Types of Matrix Effects

Matrix Effect	Description	Impact
Ion Suppression	Reduced analyte signal	Underestimation
Ion Enhancement	Increased analyte signal	Overestimation

Evaluation of matrix effects is particularly important in LC–MS/MS methods due to the presence of phospholipids, proteins, and salts that influence ionization efficiency [33].

Stability Studies

Stability studies confirm that the analyte remains unchanged during collection, processing, storage, and analysis.

Table 6. Stability Studies in Bioanalytical Validation

Stability Type	Purpose
Short-Term Stability	Stability at room temperature
Long-Term Stability	Stability during storage period
Freeze–Thaw Stability	Stability after repeated freeze–thaw cycles

Stability Type	Purpose
Bench-Top Stability	Stability during laboratory handling
Processed Sample Stability	Stability after extraction
Stock Solution Stability	Stability of standard solutions

Acceptance criteria: analyte concentrations within ±15% of nominal values [31].

Dilution Integrity

Dilution integrity ensures that samples exceeding the upper limit of quantification can be diluted without affecting accuracy or precision. It is essential when study samples fall outside the validated calibration range.

Carryover

Carryover refers to residual analyte remaining in the analytical system after analyzing high-concentration samples. Excessive carryover can affect subsequent injections and lead to inaccurate results. Proper washing procedures and system suitability tests are required [34].

Table 7. Acceptance Criteria for Major Validation Parameters

Parameter	Acceptance Criteria
Accuracy	±15% (±20% for LLOQ)
Precision	≤15% CV (≤20% for LLOQ)
Recovery	Consistent and reproducible
Selectivity	No significant interference
Stability	Within ±15% of nominal value
Calibration Standards	Minimum 75% standards acceptable
QC Samples	Minimum 67% within acceptance limits

ICH M10 Guideline Requirements

The ICH M10 guideline provides a globally harmonized framework for bioanalytical method validation and study sample analysis. It defines requirements for method development, validation experiments, calibration standards, quality control samples, stability testing, incurred sample reanalysis (ISR), and acceptance criteria for analytical runs. Adoption of ICH M10 has improved consistency among international regulatory agencies and enhanced the reliability of bioanalytical data submitted in regulatory applications [31].

Key Features of ICH M10

- Harmonized global validation requirements
- Standardized acceptance criteria
- Guidance for chromatographic and ligand-binding assays
- Detailed study sample analysis procedures
- Emphasis on data integrity and quality assurance

Regulatory Guidelines for Bioanalytical Method Validation

Bioanalytical method validation is governed by internationally recognized regulatory guidelines that ensure the generation of reliable, reproducible, and scientifically sound analytical data. Regulatory authorities across the world have established specific requirements for method development, validation, and study sample analysis to maintain data integrity and facilitate regulatory acceptance. Although the fundamental principles remain consistent among agencies, harmonization efforts have led to greater uniformity in validation practices. Among these, the **ICH M10 Guideline on Bioanalytical Method Validation and Study Sample Analysis** stands out as the most comprehensive and globally accepted framework [35,36].

The primary objective of these guidelines is to ensure that bioanalytical methods used in pharmacokinetic, toxicokinetic, bioavailability, bioequivalence, and clinical studies yield accurate and reliable results that support regulatory decision-making. Regulatory compliance is therefore a cornerstone of modern bioanalytical laboratories [37].

1. **United States Food and Drug Administration (FDA) Guideline**

The **FDA Bioanalytical Method Validation Guidance** is one of the most widely adopted regulatory documents in pharmaceutical research. It defines requirements for method validation, calibration standards, quality control samples, stability studies, incurred sample reanalysis (ISR), and documentation practices [38].

Major FDA Requirements

- Method selectivity and specificity
- Accuracy and precision assessment
- Calibration curve evaluation
- Recovery studies
- Matrix effect investigation
- Stability testing
- Dilution integrity assessment
- Incurred sample reanalysis (ISR)

The FDA emphasizes scientifically justified acceptance criteria and robust quality assurance systems throughout the analytical process [38].

2. **European Medicines Agency (EMA) Guideline**

The **EMA Guideline on Bioanalytical Method Validation** was developed to standardize bioanalytical practices within the European Union. It aligns closely with FDA recommendations but places additional emphasis on matrix effects, cross-validation, and incurred sample reanalysis [39].

Key EMA Evaluation Parameters

- Selectivity

- Carryover
- Calibration performance
- Accuracy and precision
- Matrix effects
- Stability
- Reproducibility

EMA guidance has significantly contributed to harmonizing bioanalytical practices across Europe [39].

3. International Council for Harmonisation (ICH M10)

The **ICH M10 Guideline**, finalized in 2022, represents a major milestone in global regulatory harmonization. It integrates the requirements of the FDA, EMA, PMDA (Japan), Health Canada, and other agencies into a unified framework [36].

Key Areas Covered by ICH M10

- Method development and validation
- Calibration standards and QC samples
- Chromatographic and ligand-binding assays
- Stability studies
- Study sample analysis
- Incurred sample reanalysis
- Cross-validation
- Documentation and reporting requirements

Implementation of ICH M10 has minimized regional differences and facilitated global drug development programs [36].

4. World Health Organization (WHO) Guideline

The **WHO Guideline** provides direction for bioanalytical method validation, particularly supporting generic medicines and public health programs. WHO recommendations emphasize method reliability, reproducibility, and suitability for bioequivalence studies conducted worldwide [40].

WHO Focus Areas

- Validation of analytical procedures
- Good laboratory practices
- Quality assurance systems
- Bioequivalence studies
- Generic drug evaluation

WHO guidance is especially vital in developing countries where harmonized analytical standards ensure medicine quality [40].

5. Organisation for Economic Co-operation and Development (OECD)

The **OECD Principles of Good Laboratory Practice (GLP)** establish quality standards for non-clinical safety studies. Although not exclusively focused on bioanalytical validation, they provide a foundational framework for laboratory operations, documentation, personnel training, equipment qualification, and data integrity [41].

Key OECD Principles

- Standard operating procedures (SOPs)
- Documentation practices
- Quality assurance audits
- Equipment calibration and maintenance
- Personnel competency requirements

Compliance with OECD-GLP enhances the credibility and regulatory acceptance of bioanalytical data [41].

Comparative Analysis of Regulatory Guidelines

Although FDA, EMA, WHO, and ICH M10 guidelines share similar scientific principles, historical differences existed in validation requirements and acceptance criteria. The introduction of ICH M10 has significantly reduced these discrepancies, establishing a unified global standard.

Table 8. Comparison of Major Regulatory Guidelines

Parameter	FDA	EMA	ICH M 10	WHO
Accuracy & Precision	✓	✓	✓	✓
Matrix Effect Evaluation	✓	✓	✓	✓
Stability Studies	✓	✓	✓	✓
Incurred Sample Reanalysis	✓	✓	✓	Recommended
Cross Validation	Limited	Required	Required	Recommended
Ligand-Binding Assays	✓	✓	✓	Limited
Global Harmonization	Partial	Partial	Extensive	Moderate

Importance of Regulatory Compliance

Regulatory compliance ensures that bioanalytical data generated during pharmaceutical development are scientifically credible, reproducible, and acceptable to health authorities. Non-compliance may result in study rejection, delays in product approval, increased development costs, and compromised patient safety [37,42].

Benefits of Compliance

- Enhanced data reliability
- Improved regulatory acceptance
- Reduced study repetition
- Increased patient safety
- Global acceptance of analytical data

Thus, adherence to established regulatory guidelines is a fundamental requirement for all bioanalytical laboratories engaged in pharmaceutical research and development.

Table 9. Regulatory Acceptance Criteria for Validation Parameters

Validation Parameter	FDA	EMA	ICH M10
Accuracy	±15%	±15%	±15%
Accuracy at LLOQ	±20%	±20%	±20%
Precision	≤15% CV	≤15% CV	≤15% CV
Precision at LLOQ	≤20% CV	≤20% CV	≤20% CV
Stability Acceptance	±15%	±15%	±15%
Matrix Effect Evaluation	Required	Required	Required
Incurred Sample Reanalysis	Required	Required	Required
Cross Validation	Recommended	Required	Required

Challenges and Recent Advances in Bioanalysis

The field of bioanalysis has evolved dramatically over the past two decades, driven by the increasing complexity of pharmaceutical compounds, stringent regulatory requirements, and the demand for highly sensitive analytical methods. Modern therapeutics—including biologics, gene therapies, antibody–drug conjugates, and nanomedicines—have introduced new analytical hurdles that conventional techniques often struggle to address. At the same time, innovations in chromatography, mass spectrometry, automation, microsampling, and data science have significantly expanded bioanalytical capabilities [43,44].

Despite these advances, bioanalytical scientists continue to face persistent challenges such as matrix effects, analyte instability, limited sample volumes, biomarker variability, and the need for high-throughput data processing. Addressing these issues is critical to generating reliable, regulatory-compliant data [45].

Challenges in Bioanalysis

1. **Matrix Effects** Endogenous compounds (phospholipids, proteins, salts, metabolites) can suppress or enhance analyte ionization in LC–MS/MS assays, leading to inaccurate quantification [46].

Consequences of Matrix Effects

- Reduced analytical sensitivity
- Poor reproducibility
- Signal suppression
- Signal enhancement
- Inaccurate concentration measurements

Mitigation requires robust sample preparation and systematic matrix effect evaluation during method validation.

2. **Analyte Instability** Pharmaceutical compounds may degrade due to hydrolysis, oxidation, enzymatic metabolism, photolysis, or adsorption during collection and storage [47].

Common Stability Concerns

- Freeze–thaw degradation
- Long-term storage instability
- Bench-top degradation
- Processed sample instability

Comprehensive stability studies are essential to preserve data integrity.

3. **Limited Sample Volume** Paediatric medicine, personalized medicine, and preclinical studies often require analysis of microliter volumes. Traditional approaches demand larger samples, creating challenges when volumes are restricted [48].

This has accelerated the adoption of micro sampling technologies and ultra-sensitive analytical platforms.

4. **Complexity of Biologics** Biologics such as monoclonal antibodies, recombinant proteins, peptides, gene therapies, and antibody–drug conjugates present unique analytical challenges [49].

Challenges Associated with Biologics

- Immunogenicity assessment
- Structural characterization
- Multiple molecular forms
- Post-translational modifications
- Stability monitoring

Specialized methodologies are required to address their heterogeneity and complexity.

5. **Biomarker Variability** Biomarkers are increasingly central to drug development and personalized medicine. However, biological variability among individuals complicates quantification and interpretation [50].

Factors Contributing to Variability

- Age
- Gender
- Genetics
- Disease state
- Environmental exposure

Standardized procedures and rigorous validation strategies are necessary to ensure reliable biomarker measurement.

Recent Advances in Bioanalysis

1. **Ultra-Performance Liquid Chromatography (UPLC)** UPLC represents a major advancement over conventional HPLC. By employing smaller particle-size columns and higher operating pressures, UPLC achieves superior

chromatographic resolution, faster analysis, and enhanced sensitivity [51].

Advantages of UPLC

- Reduced run times
- Higher sensitivity
- Better separation efficiency
- Lower solvent consumption
- Increased sample throughput

UPLC is now widely integrated with mass spectrometry platforms for modern bioanalytical applications.

2. **High-Resolution Mass Spectrometry (HRMS)** HRMS has transformed bioanalysis by enabling precise mass measurements and accurate identification of analytes, metabolites, and impurities. Instruments such as Orbitrap and Time-of-Flight (TOF) deliver superior mass accuracy and resolving power compared with conventional systems [52].

Applications of HRMS

- Metabolite identification
- Biomarker discovery
- Proteomics
- Metabolomics
- Impurity profiling

3. **Dried Blood Spot (DBS) Sampling** DBS is an innovative microsampling technique where small blood volumes are collected on filter paper and dried prior to analysis. It offers practical advantages over traditional venous blood collection [53].

Benefits of DBS

- Minimal blood volume requirement
- Easier transportation
- Improved sample stability
- Reduced storage costs
- Enhanced patient compliance

DBS is increasingly applied in pediatric studies, remote clinical trials, and pharmacokinetic investigations.

4. **Volumetric Absorptive Microsampling (VAMS)** VAMS was developed to overcome hematocrit-related limitations of DBS. VAMS devices collect fixed blood volumes, improving analytical accuracy and reproducibility [54].

Advantages of VAMS

- Fixed sample volume collection
- Improved precision
- Simplified sampling procedure
- Better suitability for home-based sampling

5. **Automation in Bioanalysis** Automation has revolutionized laboratory workflows, enhancing efficiency and reproducibility. Robotic systems are now routinely used for sample preparation, extraction, liquid handling, and analytical processes [55].

Benefits of Automation

- Reduced human error
- Increased throughput
- Improved reproducibility
- Reduced labor costs
- Enhanced regulatory compliance

Automation is particularly valuable in large-scale pharmacokinetic and bioequivalence studies.

6. **Biomarker-Based Bioanalysis** The rise of precision medicine has elevated the importance of biomarker quantification. Modern bioanalytical methods can simultaneously measure drugs and biomarkers, offering deeper insights into treatment response [50].

Applications of Biomarker-Based Bioanalysis

- Oncology
- Cardiovascular diseases
- Neurological disorders
- Immunological diseases
- Personalized medicine

7. **Artificial Intelligence and Machine Learning (AI/ML)** AI and ML are emerging as powerful tools in bioanalysis, enabling automated data processing, pattern recognition, chromatographic optimization, and predictive modeling [56].

Potential Applications of AI/ML

- Peak identification
- Data interpretation
- Metabolite prediction
- Method optimization
- Quality control monitoring

AI-driven bioanalytical systems are expected to enhance efficiency, reduce variability, and accelerate drug development.

Table 10. Recent Technological Advances in Bioanalysis

Technology	Major Advantage	Application
UPLC	Faster separation	Routine bioanalysis
HRMS	High mass accuracy	Metabolomics, biomarker studies
LC–MS/MS	High sensitivity	PK, TK, BA/BE studies
DBS	Minimal sample volume	Pediatric studies
VAMS	Precise microsampling	Clinical research
Automation	High throughput	Large-scale studies
AI/ML	Intelligent data analysis	Predictive bioanalysis

FUTURE PERSPECTIVES IN BIOANALYSIS

The future trajectory of bioanalysis will be shaped by continuous advances in analytical instrumentation, miniaturization, automation, and computational technologies. Emerging disciplines such as metabolomics, proteomics, pharmacogenomics, and systems biology will demand increasingly sophisticated analytical approaches capable of generating comprehensive biological datasets [56,57].

Integration of artificial intelligence, cloud computing, and real-time monitoring is anticipated to transform bioanalytical workflows, enabling faster decision-making and improved efficiency throughout drug development.

CONCLUSION

Bioanalysis has firmly established itself as an indispensable pillar of modern pharmaceutical research and development, providing critical insights into the absorption, distribution, metabolism, excretion, efficacy, and safety of therapeutic agents. From early drug discovery and lead optimization through clinical trials, regulatory approval, and post-marketing surveillance, bioanalytical methods generate the quantitative data necessary for informed scientific and regulatory decision-making. The reliability of these data depends on the development of robust analytical methods and their comprehensive validation according to internationally accepted standards [59,60].

Advances in analytical technologies—particularly LC–MS/MS, high-resolution mass spectrometry, ligand-binding assays, and microsampling approaches—have significantly enhanced sensitivity, selectivity, and efficiency. At the same time, the increasing complexity of biologics, biosimilars, gene therapies, and personalized medicines has expanded the scope of bioanalysis and introduced new challenges. To address these, continuous improvements in sample preparation, automation, data processing, and AI-based analytical tools are being incorporated into modern workflows [61,62].

Regulatory harmonization through the implementation of the ICH M10 guideline has further strengthened the quality and consistency of bioanalytical studies worldwide. By establishing standardized requirements for method validation, study sample analysis, stability assessment, and data reporting, these guidelines ensure the generation of reliable and reproducible analytical results that support global drug development programs [63].

In conclusion, bioanalysis remains a cornerstone of evidence-based pharmaceutical development. Continued technological innovation, regulatory harmonization, and integration of advanced analytical approaches will further enhance its role in ensuring drug quality, patient safety, and therapeutic effectiveness. As healthcare advances toward precision medicine and complex biologic therapies, bioanalysis will continue to evolve as a critical scientific discipline supporting the future of pharmaceutical and clinical research [60,63].

REFERENCES

1. Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation—a revisit with a decade of progress. Pharm Res. 2000;17(12):1551–1557.
2. Karnes HT, March C. Precision, accuracy, and data acceptance criteria in biopharmaceutical analysis. Pharm Res. 1993;10(10):1420–1426.
3. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. Quantitative bioanalytical methods validation and implementation. Pharm Res. 2007;24(10):1962–1973.
4. Reid E, Wilson ID. Analysis for Drugs and Metabolites. Cambridge: Royal Society of Chemistry; 1990.
5. Wells DA. High Throughput Bioanalytical Sample Preparation. Amsterdam: Elsevier; 2003.
6. Mehta MU. Bioanalytical method development and validation. Pharm Methods. 2012;3(1):12–18.
7. Lee JW. Method validation and sample analysis. Pharm Res. 2005;22(4):499–511.
8. Shah VP. Bioanalytical method validation. Pharm Res. 1992;9(4):588–592.
9. Findlay JWA, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, et al. Validation of immunoassays. J Pharm Biomed Anal. 2000;21(6):1249–1273.
10. Rozet E, Hubert P, Ziemons E, Oprean R, Rudaz S, Boulanger B. Validation of analytical procedures. J Chromatogr A. 2007;1158(1–2):111–125.
11. Hubert P, Chiap P, Crommen J, Boulanger B, Chapuzet E, Mercier N, et al. Validation of chromatographic methods. Anal Chim Acta. 1999;391(2):135–148.
12. Hartmann C, Smeyers-Verbeke J, Massart DL, McDowall RD. Validation of bioanalytical methods. J Pharm Biomed Anal. 1998;17(2):193–218.
13. Peters FT, Drummer OH, Musshoff F. Validation of analytical procedures. Forensic Sci Int. 2007;165(2–3):216–224.
14. Taylor PJ. Matrix effects in LC-MS/MS. Clin Biochem. 2005;38(4):328–334.

15. Jemal M, Ouyang Z, Teitz D. Quantitative bioanalysis by LC-MS/MS. Biomed Chromatogr. 2003;17(1):1–15.
16. Xu RN, Fan L, Rieser MJ, El-Shourbagy TA. Recent advances in LC-MS/MS. J Pharm Biomed Anal. 2007;44(2):342–355.
17. Niessen WMA. Progress in LC-MS instrumentation. J Chromatogr A. 2003;1000(1–2):413–436.
18. Lee MS. LC/MS Applications in Drug Development. New York: Wiley; 2002.
19. Niessen WMA. Liquid Chromatography–Mass Spectrometry. 3rd ed. Boca Raton: CRC Press; 2006.
20. Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR. Systematic evaluation of matrix effects. J Chromatogr B. 2007;852(1–2):22–34.
21. Matuszewski BK. Matrix effect strategies. Anal Chem. 2006;78(21):7615–7624.
22. Bonfiglio R, King RC, Olah TV, Merkle K. Matrix-induced ion suppression. Rapid Commun Mass Spectrom. 1999;13(12):1175–1185.
23. Nowatzke W, Woolf E. Evaluation of analyte stability. AAPS J. 2007;9:E117–E122.
24. Timm U, Wall M, Dell D. Drug stability in biological fluids. J Pharm Sci. 1985;74(9):972–977.
25. Korfmacher WA. Principles and applications of LC-MS. Drug Discov Today. 2005;10(20):1357–1367.
26. Jemal M. High-throughput bioanalysis. Rapid Commun Mass Spectrom. 2000;14(6):422–429.
27. Miller KJ, Bowsher RR, Celniker A, Gibbons J. Validation for macromolecules. Pharm Res. 2001;18(9):1373–1379.
28. Findlay JWA, Dillard RF. Appropriate validation. J Pharm Biomed Anal. 2007;43(4):1035–1044.
29. Rao KR, Kumar KS. Quality assurance viewpoint. J Pharm Sci Res. 2009;1(3):1–10.
30. Thompson M, Ellison SLR, Wood R. Harmonized validation guidelines. Pure Appl Chem. 2002;74(5):835–855.
31. Wood R. How to validate analytical methods. Trends Anal Chem. 2005;18:624–632.
32. Kallner A. Uncertainty of measurement. Scand J Clin Lab Invest. 1999;59(7):513–516.
33. McDowall RD. Laboratory information systems. Anal Chim Acta. 2007;54:149–158.
34. European Medicines Agency. Guideline on Bioanalytical Method Validation. London: EMA; 2011.
35. U.S. Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. Silver Spring, MD: FDA; 2018.
36. International Council for Harmonisation. ICH M10 Guideline on Bioanalytical Method Validation and Study Sample Analysis. Geneva: ICH; 2022.
37. World Health Organization. Bioanalytical Method Validation Guidelines. Geneva: WHO; 2011.
38. OECD. Principles of Good Laboratory Practice. Paris: OECD Publishing; 1998.
39. González O, Blanco ME, Iriarte G, Bartolomé L, Maguregui MI, Alonso RM. Bioanalytical chromatographic validation. J Chromatogr A. 2014;1353:10–27.
40. Surendra B, DeStefano A. Small molecule validation. AAPS J. 2007;9:E109–E114.
41. Dadgar D, Burnett PE. Selectivity and stability issues. J Pharm Biomed Anal. 1995;14:23–31.
42. Moein MM, El Beqqali A, Abdel-Rehim M. Method development strategies. J Chromatogr B. 2017;1043:3–11.
43. Chiu ML, Lawi W, Snyder ST, Wong PK, Liao JC, Gau V. Matrix effects. J Assoc Lab Autom. 2010;15(3):233–242.
44. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. Matrix effect evaluation. J Chromatogr B. 2009;877(23):2198–2207.
45. Swartz ME. UPLC review. J Liq Chromatogr Relat Technol. 2005;28(7–8):1253–1263.
46. Zhang Z, Wu S, Stenoien DL, Pasa-Tolic L. High-resolution mass spectrometry. Mass Spectrom Rev. 2014;33(3):183–214.
47. Denniff P, Spooner N. Dried blood spots. Bioanalysis. 2010;2(8):1385–1395.
48. Spooner N, Lad R, Barfield M. Volumetric absorptive microsampling. Bioanalysis. 2015;7(6):653–659.
49. Topol EJ. High-performance medicine. Nat Med. 2019;25(1):44–56.
50. Wishart DS. Metabolomics and precision medicine. Nat Rev Drug Discov. 2016;15(7):473–484.
51. Lee JW, Kelley M, King LE, Yang J. Ligand-binding assay validation. AAPS J. 2006;8(4):E650–E660.
52. Rocci ML, Devanarayan V. Immunogenicity testing. Bioanalysis. 2011;3(18):2087–2103.
53. Kaur P, Sharma P. Microsampling technologies in bioanalysis. Biomed Chromatogr. 2018;32:e4154.
54. Timmerman P, White S, Cobb Z. Microsampling applications. Bioanalysis. 2019;11(21):1941–1955.

55. Jemal M, Schuster A, Whigan DB. High-throughput LC-MS/MS. Rapid Commun Mass Spectrom. 2003;17(15):1723–1734.
56. Topol EJ. Artificial intelligence in medicine. Nat Med. 2019;25(1):44–56.
57. Wishart DS. Metabolomics applications. Nat Rev Drug Discov. 2016;15(7):473–484.
58. International Council for Harmonisation. ICH M10 Guideline. Geneva: ICH; 2022.
59. Rao KR, Kumar KS. Bioanalytical validation: auditor viewpoint. J Pharm Sci Res. 2009;1(3):1–10.
60. Moein MM, El Beqqali A, Abdel-Rehim M. Bioanalytical method development and validation. J Chromatogr B. 2017;1043:3–11.
61. González O, Blanco ME, Iriarte G, Bartolomé L, Maguregui MI, Alonso RM. Validation according to regulations. J Chromatogr A. 2014;1353:10–27.
62. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. LC-MS/MS assay validation. J Chromatogr B. 2009;877(23):2198–2207.
63. International Council for Harmonisation. ICH M10 Guideline on Bioanalytical Method Validation and Study Sample Analysis. Geneva: ICH; 2022.